Coya Therapeutics Publishes Study Linking Biomarkers to ALS Clinical Outcomes
Coya Therapeutics has announced the publication of a study demonstrating the correlation between longitudinal biomarker data and clinical outcomes in ALS patients. The study evaluated serum biomarkers such as 4-hydroxy-2-nonenal (4-HNE), lipopolysaccharide binding protein (LBP), and neurofilament light chain (NfL) in 100 ALS patients and 100 healthy controls. The findings show significant correlations between these biomarkers and survival rates, supporting the mechanistic rationale for Coya's COYA 302 treatment. COYA 302, an investigational biologic combination therapy, aims to enhance the anti-inflammatory function of regulatory T cells and suppress inflammation. The study's results are consistent with previous clinical findings, indicating potential benefits in slowing ALS progression. 
